AstraZeneca (AZN) has announced its acquisition of Modella AI, a company specializing in biomedical artificial intelligence, to enhance its cancer treatment development. The acquisition aims to integrate Modella AI's advanced AI models and agents into AstraZeneca's oncology research and development, facilitating new biological and clinical insights and improving data workflow efficiency. Although the financial terms of the deal remain undisclosed, the collaboration between AstraZeneca and Modella AI began in July 2025 through a multi-year agreement.
https://www.gurufocus.com/news/4113991/astrazeneca-azn-acquires-modella-ai-to-boost-cancer-research
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.